Celprogen develops neuronal stem cells to take care of Alzheimer’s Celprogen has developed neuronal stem cells which can be differentiated into neurons as an alternative for Cell based therapy for neurological diseases including Alzheimer’s sufferers click to be linked . The pre-clinical studies are very promising, in vivo, showing improvement in short and long term memory in experimental models which procedure may someday become an alternative solution therapy for Alzheimer’s patients. Celprogen has began their Collaborations with Dr. D.K. Lahiri and Dr. B. Ray of Indiana University School of Medicine, who are extremely acclaimed and international experts in the field of drug development in Alzheimer’s disease.
Cempra’s solithromycin demonstrates efficacy comparable to levofloxacin for CABP treatment Cempra Pharmaceuticals today announced results from its Stage II clinical trial investigating the efficacy, tolerability and protection of oral administration of our fourth era macrolide, solithromycin , a fluoroketolide antibiotic, in comparison to oral levofloxacin for the treating community-acquired bacterial pneumonia .D., Shields Warren-Mallinckrodt Professor of Medical Analysis at Harvard Medical College.’ David Oldach, M.D., senior vice president of clinical research of Cempra added, ‘Outcomes out of this trial indicate that CEM-101 is something candidate with efficacy much like levofloxacin, the existing standard of care for the treatment of CABP and with a good safety profile.